Late-breaking Phase 3 REDUCE-2 data show clinically meaningful and durable serum urate lowering with pozdeutinurad

What happened: Sobi presented late-breaking Phase 3 REDUCE-2 data at ACR Convergence 2026 showing pozdeutinurad (AR882), an investigational once-daily oral URAT1 inhibitor, lowered serum urate in patients with uncontrolled gout. Key numbers: 811 patients randomized to pozdeutinurad 75 mg, 50 mg or placebo. Why it matters: The study met its primary endpoint with a safety profile generally comparable to placebo, and investigators said many patients remain inadequately controlled on currently available oral therapies. Sobi called the first presentation of these data an important milestone.

Late-breaking Phase 3 REDUCE-2 data show clinically meaningful, durable serum urate lowering with pozdeutinurad.

Late-breaking Phase 3 REDUCE-2 data show clinically meaningful, durable serum urate lowering with pozdeutinurad. — impact context not separately stored; see What changed.